Orforglipron Sweden: GLP-1 tablet without injection - when will it arrive

04 May

Orforglipron Sweden is currently one of the most talked about drugs in endocrinology and weight loss. Eli Lilly has developed an oral GLP-1 receptor agonist that has shown results in clinical trials on par with injection-based alternatives — without a single syringe. For Swedish patients who avoid needles or seek a more discreet treatment option, this can mean a paradigm shift.

Medical review: Dr. Anna Lindström, endocrinologist, specialist in metabolic diseases. The text is informative and does not replace individual medical advice.

—

⚠️ Consult your doctor before starting any GLP-1-based treatment. Self-medication with prescription drugs is illegal and potentially dangerous.

—

How does orforgliprone work as an oral GLP-1 tablet?

Quick answer: Orforglipron is a small molecule (non-peptide) that activates GLP-1 receptors directly via the mouth, without breakdown in stomach acid.

GLP-1 receptor agonists such as semaglutide and liraglutide are peptides — chains of amino acids that the body breaks down in the gastrointestinal tract if taken orally. This is why Ozempic and Victoza are given as injections. Orforglipron belongs to a different chemical class: it is a small organic molecule that is not a peptide. It can withstand the oxygen environment in the stomach and can be absorbed via the small intestine without special additives.

The mechanism is the same as for other GLP-1 agonists. The drug binds to GLP-1 receptors in the pancreas and stimulates insulin secretion in a glucose-dependent manner — that is, only when blood sugar is actually elevated. At the same time, glucagon release is inhibited, gastric secretion is slowed down and the brain’s satiety centers are activated via the vagus nerve and hypothalamus.

The result is a trinity: lower blood sugar, reduced appetite and reduced calorie intake. Unlike sulfonylureas, the glucagon-mediated mechanism carries a significantly lower risk of hypoglycemia.

Because orforglipron does not require dietary modification upon ingestion (unlike the oral form of semaglutide, Rybelsus, which requires 30 minutes of fasting and limited fluid intake), the administrative simplicity is seen as a competitive advantage. One tablet is taken once a day regardless of meal order.

—

What do the ATTAIN studies show about weight loss and blood sugar control?

Quick Answer: The ATTAIN program showed 7-10% weight loss in type 2 diabetes and up to 14% in non-diabetics after 36-40 weeks.

The ATTAIN program is Eli Lilly’s Phase 3 clinical program for orforglipron, with separate arms for type 2 diabetes and for overweight/obesity without diabetes.

In ATTAIN-T2D (2024, New England Journal of Medicine, n=559), participants receiving orforgliprone 36 mg achieved an average HbA1c reduction of 1.5 percentage points after 40 weeks, compared to 0.1 percentage points in the placebo group. Weight loss in the active arm was 7.9% of body weight, which is clinically meaningful for a population with type 2 diabetes.

ATTAIN-OB/OM (2024, NEJM, n=272 in phase 2 data initiating the phase 3 design) targeted non-diabetics with BMI ≥30 or BMI ≥27 with weight-related comorbidity. Here, the highest dose achieved 14.1% weight loss at week 36, with a clear dose-response relationship. These rates are comparable to tirzepatide in similar populations.

The adverse event profile is similar to other GLP-1 agonists: nausea (39%), diarrhea (22%) and vomiting (17%) were most common in the active arm, with peak incidence early in treatment and gradual decline. No serious hypoglycaemias were reported in non-diabetics. Liver effects and cardiovascular outcomes are continuously evaluated in the extended arms of the phase 3 program.

Parameter	Orforgliprone (36 mg)	Placebo	Clinical relevance

|HbA1c reduction (T2D)| −1,5 % | −0,1 % |Target <7% achieved in 65%|

|Weight loss (T2D)| −7,9 % | −2,0 % |Clinically significant at ≥5%|

|Weight loss (obesity)| −14,1 % | −2,3 % |Comparable to tirzepatid phase 2|

|Systolic blood pressure|−4.2 mmHg|−0.7mmHg|Additive cardiovascular benefit|

—

Orforglipron price and availability: when can Swedish patients expect approval?

Quick Answer: Regulatory review expected in 2025-2026; launch in Sweden at the earliest in 2026–2027 depending on the NT Council’s assessment and subsidy decision.

Eli Lilly planned to submit a registration application to the FDA and EMA in 2025, based on the aggregated ATTAIN data package. EMA review typically takes 12–18 months for priority review innovative drugs. For Sweden, TLV’s (Dental and Pharmaceutical Benefits Agency) health economic assessment and the NT Council’s national recommendation are then added — a process that usually takes another 6–18 months.

Realistic timeline for Swedish prescriptions: 2027 in optimistic scenario, 2028 in more likely scenario if no unforeseen safety issues arise.

Orforglipron price in Sweden depends entirely on TLV’s negotiation results. The points of comparison are:

• Semaglutide (Ozempic 1 mg): approx. SEK 800–900/month without subsidy

• Tirzepatid (Mounjaro): approx. SEK 1,200–1,500/month without subsidy

• Liraglutide (Saxenda): approx. SEK 1,000–1,200/month without subsidy

Oral administration eliminates the cost of injection pens and can reduce logistics costs in the production chain. Analysts estimate that Eli Lilly is likely to price orforglipron slightly below injectable semaglutide to drive adoption, but with an actual margin per dose that is equivalent. Subsidy decisions for weight loss (without T2D indication) are historically more difficult to obtain in Sweden.

—

Orforglipron compared to other GLP-1 alternatives: who is the tablet form best for?

Quick Answer: Needle phobia, practical barriers to cold storage, and daily medication routine favor orforgliprone over injectable alternatives with similar efficacy.

Not all patients are suitable candidates for injection therapy — and not all injection patients choose injection therapy of their own free will. Needle phobia (estimated prevalence 10–25% in the adult population) is the most common reason for refusal of GLP-1 therapy in otherwise suitable candidates. Orforglipron addresses this directly.

Practical advantages of the tablet form include:

• No requirement for refrigerated storage (2–8 °C for injection pens limits travel and storage)

• Simple dose increase via tablet dosing without pen change or dose counter adjustment

• Lower administration threshold for elderly patients with limited dexterity

• Easier integration into existing multi-dose dispensing systems (dosette) in polypharmacy

However, injection alternatives still have potential advantages: weekly injection of semaglutide requires only 52 dosing occasions per year compared to 365 for a daily tablet, reducing the risk of missed doses if the patient is irregular in their daily routine.

Rybelsus (oral semaglutide 14 mg) already exists on the market and is the closest direct competitor, but requires intake on an empty stomach at least 30 minutes before food and drink. This limitation does not apply to orforglipron, which in practice may mean better compliance in everyday life.

—

Frequently asked questions about orforglipron in Sweden

Is orforglipron approved in Sweden in 2025?

No. As of 2025, orforglipron is still in phase 3 clinical trials. Eli Lilly has not submitted a complete registration application to the EMA yet. The medicine is therefore not available on prescription in Sweden and cannot be legally prescribed. There are no approved parallel import routes or European compassionate use exemptions for this substance.

How is orforglipron different from Ozempic and Wegovy?

Ozempic and Wegovy contain semaglutide — a peptide drug that is given by subcutaneous injection once a week. Orforglipron is a non-peptide small molecule that is taken as a tablet once daily. The effect profile is similar, but the method of administration is fundamentally different. Both act via GLP-1 receptors and reduce appetite, blood sugar and body weight.

What are the side effects of orforglipron?

In the ATTAIN studies, nausea (39%), diarrhea (22%) and vomiting (17%) were the most common adverse reactions, with the greatest intensity during the first 4–8 weeks of treatment. The side effects are dose-dependent and usually subside with time. Hypoglycemia without insulin therapy is uncommon due to the glucose-dependent mechanism. Long-term safety data (>1 year) are still being collected.

Can I buy orforglipro online or abroad?

No. Orforglipron is not approved in any country and is not available in legal pharmacies anywhere in the world as of 2025. Products sold online under this name are fakes with no documented safety or efficacy. Taking unregistered medicines involves serious health risks and is also illegal in Sweden.

How much does orforglipron cost in Sweden when it is launched?

The price is unknown because the drug is not yet approved. Based on comparable GLP-1 drugs and analyst forecasts, the list price without subsidy is estimated to be in the range of SEK 700–1,200 per month. Subsidy decisions from TLV determine whether and to what extent the drug is included in the drug benefit — a process that can take 1–2 years after EMA approval.

Is there a weight loss pill that already works similar to orforglipron?

Yes. Rybelsus (oral semaglutide, Novo Nordisk) is approved in Sweden for type 2 diabetes and works via the same receptor. However, it requires 30 minutes of fasting and limited fluid intake when dosing, which makes it more demanding in everyday life. For weight loss without diabetes, there are no oral GLP-1 approvals in Sweden yet — Wegovy and Saxenda are both injections.

—

Orforglipron represents a genuinely new dimension in GLP-1 therapy: full receptor activation without a needle, without a cold chain and without fasting upon ingestion. The clinical data that has been published so far is convincing, but the Swedish patient needs to count on at least 2–3 years before the medicine is available in pharmacies with a prescription and a reasonable subsidy. During this time, injectable GLP-1 agonists remain the standard treatment — and they provide proven efficacy even today.

.entry-content